Background. Multivisceral transplantation (MVtx) involves simultaneous transplantation of the intestine with other organs, often including the pancreas. The pancreas portion of the graft has always been approached with caution because allograft pancreatitis, rejection or technical complications may be devastating in this setting. We reviewed our experience with multivisceral grafts that included the entire pancreas. Methods. Twenty-five patients received 27 MVtx that included the entire pancreas between July 2003 and November 2006. In five, a modified MVtx with preservation of the native liver was performed. Two patients required retransplantation for severe rejection. Insulin requirements, graft and patient survival were determined at 6-months posttransplant. Serum amylase and lipase levels were analyzed on postoperative days 3, 7, 30, and 180. Results. Twenty of 25 patients with a transplant pancreas graft were alive at 6-months posttransplant. Median serum amylase and lipase levels posttransplant were normal at all time points. One patient exhibited elevation of amylase and lipase at the time of severe acute cellular rejection of the intestinal graft, likely representing simultaneous pancreas allograft rejection, although this was not confirmed by biopsy. There were no episodes of allograft pancreatitis or technical complications. Once weaned from hyperalimentation, all patients remained normoglycemic and insulinindependent 6-months posttransplant. Conclusion. In this series, there were no postoperative pancreatic complications, no episode of isolated pancreas allograft rejection, and no loss of pancreatic graft function. None of the five deaths were related to pancreatic graft complications.
M ultivisceral transplantation (MVtx) has become the treatment of choice for patients with short bowel syndrome associated with abdominal catastrophes such as extensive abdominal trauma, selective cases of intrabdominal malignancies with benign or low grade tumors involving the mesenteric root, certain motility disorders of the gastrointestinal tract and selective cases of diffuse splanchnic thrombosis (1) (2) (3) . In addition, a composite liver-pancreas-small intestine graft is frequently used for patients with intestinal failure and irreversible liver disease (4, 5) . The type of graft can now be tailored according to the indication and liver function. The common element in all the variants is transplantation of the small bowel (6) .
The pancreas portion of the multivisceral graft has always been approached with a certain degree of caution because allograft pancreatitis, rejection or technical complications may be devastating in this setting. Many centers have reported an approach where a near total graft pancreatectomy was required to avoid these issues (5, 7) . It has always been our practice to include the entire pancreas as a component of all multivisceral grafts.
Little information has been published regarding complications, rejection, and postoperative function of the pancreatic portion of the graft. Existing reports comment only on catastrophic outcomes discovered at autopsy or after removal of a failed graft (8) . We describe our experience with routine preservation of the entire pancreas as a component of the multivisceral graft.
MATERIALS AND METHODS
Twenty-five patients received 27 MVtx that included the entire pancreas between July 2003 and November 2006. Indications for transplant and patient demographics are summarized in Table 1 . The first 13 grafts were flushed and preserved in University of Wisconsin solution (UW) and the latter 14 were flushed and preserved in histidine-tryptophanketoglutarate solution (HTK). We have used different volumes of both solutions depending on the donor's weight. In donors with 25 kg or less, 1500 mL of HTK and 1200 mL of UW was used. In the adult grafts, 3000 mL of UW and 4000 mL of HTK was used to flush the multivisceral graft. Cold ischemia time ranged from 5 to 14 hr (median 8 hr) and warm ischemic times from 13 to 47 min (median 23 min). Induction therapy was performed using rabbit antithymocyte globulin (10 mg/kg) divided into five doses, which were given on postoperative days 0, 2, 4, 6, and 8. Rituximab (150 mg/m 2 ) was given on posttransplant day 3. Methylprednisolone was used as premedication for both rabbit antithymocyte globulin and Rituximab and subsequently tapered over 1 to 6 months. Surveillance of the intestinal graft was performed with the use of magnification endoscopy through the chim-ney ileostomy twice a week for the first 2 weeks, weekly for the next 2 months and monthly until the ileostomy was taken down. Maintenance immunosuppression was with tacrolimus monotherapy in most cases with goal level 12 to 15 ng/dL in the first month. Mild acute cellular rejection was treated with intravenous solumedrol. Moderate and severe rejection was treated with another course of thymoglobulin (6 mg/kg). All patients received cytomegalovirus and Pneumocystis carinii prophylaxis. Enteral feedings were introduced between day 5 and 7. Once 50% of the caloric requirements were achieved either orally or with enteral tube feeding, parenteral nutrition was discontinued. Serum amylase and lipase levels were analyzed on postoperative days 3, 7, 30, and 180. Patient and graft survival as well as insulin requirements were established at 6 months.
RESULTS
Twenty of 25 patients with a transplant pancreas graft were alive at 6-months postmultivisceral transplant. Median serum amylase and lipase levels posttransplant were within normal limits at all time points. One patient exhibited elevation of amylase and lipase at the time of severe acute cellular rejection of the intestinal graft, likely representing simultaneous pancreas allograft rejection, although this was not confirmed by a biopsy. Amylase and lipase returned to normal with treatment of the rejection episode and coincided with improvement in small bowel rejection on biopsy. There were no episodes of unexplained isolated hyperamylasemia or hyperlipasemia. There were no episodes of acute allograft pancreatitis or technical complications directly related to the duodenal pancreatic complex such as pancreatic fistulae, pancreatic ascites, or pseudocysts. Once weaned from hyperalimentation, all patients remained normoglycemic and insulin-independent 6 months posttransplant.
DISCUSSION
Survival after MVtx has improved significantly over the past decade because of refinements in surgical technique and clinical management (9) .
Variations of composite small intestine grafts have all been derived from the initial "cluster" operation proposed by Starzl et al. (6) . In situations where liver replacement is required, it is currently well accepted that there is a significant advantage to leaving the pancreaticoduodenal complex intact to avoid reconstruction of the biliary system and skeletonization of the vascular structures (5, 7) . Failure to preserve these structures was previously associated with a high postoperative complication rate including biliary leaks and strictures which occurred in more than 10% of the recipients (7).
The transplanted pancreas can be entirely preserved or a near total pancreatectomy including resection of the body and tail can be performed on the back table. The disadvantage of performing a backtable pancreatectomy is the added risk of fistula from the cut pancreas surface, graft remnant pancreatitis, and diabetes (10, 11) . The actual incidence of diabetes, exocrine and endocrine function of the graft in this setting has not been reported.
Similar to the group from Miami, we have chosen the option of a multivisceral graft over a liver-pancreas-small bowel graft for patients with intestinal failure and irreversible liver disease. The reasons to this approach are as follows: a. The native stomach and pancreas can be affected by the baseline disease with residual effects of portal hypertension or severe adhesions. b. Preservation of the native pancreaticoduodenal complex requires a portocaval shunt, which adds another step to the procedure. On occasion, a venous graft needs to be placed in the native portal vein to achieve adequate length for the anastomosis. The presence of a partial or complete thrombus involving the native cava is not infrequent in these patients, precluding adequate flow for the remaining organs. c. Interruption of the arterial inflow to the native organs can be achieved in an effective and expeditious manner during MVtx by early ligation of the celiac and mesenteric arteries. Early decompression of the vascular system decreases portal hypertension and minimizes intraoperative blood loss.
Additionally, the majority of patients with intestinal failure have lost a significant portion of their abdominal domain and retention of the pancreaticoduodenal complex and enlarged spleen requires extra intrabdominal space. This lack of abdominal space restricts the acceptable size for the potential donor limiting the options for available donors. Rejection of the stomach and pancreas are very rare and are not usually observed independent of severe rejection of the small bowel. Chronic rejection of the pancreatic portion of a multivisceral graft has been reported (8) . Multivisceral transplantation recipients overall experience fewer episodes of severe rejection of the intestinal component when compared with other patients with different intestinal grafts. In our series, clinical signs of isolated rejection of the pancreas graft were not found and hyperglycemia was only present while the patients were receiving hyperalimentation.
Results of transplantation of the pancreas as a whole organ have improved in the past decade, however long-term function of an isolated pancreas graft at 1 and 3 years is only 76% and 62%, respectively. The majority of pancreas allograft failures in these recipients are related to technical failures and rejection. When the pancreas is included as a component of a multivisceral graft, both of these features are reduced. The pancreas is located at the center of the graft with minimal risk for vascular thrombosis when compared with whole organ pancreas transplantation. In addition, the graft survival in the pancreas transplantation literature is far superior when the graft is placed simultaneously with another organ that can be monitored for rejection (usually a kidney). Pancreas graft survival at 1 and 3 years for a simultaneous pancreas and kidney increases to 85% and 77%, respectively. In the case of MVtx, the intestine is constantly surveyed for signs of rejection.
Of note, more than half of the reported multivisceral allografts in this report were preserved in HTK, as opposed to UW solution. This is likely the largest reported series of small intestine or multivisceral grafts preserved in this solution. Other centers have publicly reported concerns about the pancreas portion of the multivisceral allograft with this preservation solution. Our group has reported the largest series of pancreas transplantations performed using HTK preservation solution and has failed to demonstrate any difference when compared with UW (12, 13) . We have similarly found no increase in pancreatitis, pancreatic edema or pancreas allograft loss in the multivisceral patient population related to this preservation solution.
In summary, there were no postoperative pancreatic complications in our series, no episodes of isolated pancreas rejection, and no loss of pancreatic graft function. None of the five patients deaths were related to pancreatic complications or dysfunction. This data supports the safe inclusion of the entire pancreas in MVtx.
